The Relative Strength (RS) Rating for Novartis ADR headed into a higher percentile Tuesday, as it got a lift from 68 to 72.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the market's biggest winners typically have an RS Rating of above 80 in the early stages of their moves. See if Novartis ADR can continue to rebound and hit that benchmark.
Novartis ADR is working on a consolidation with a 116.91 buy point. See if it can break out in volume at least 40% above average.
Novartis ADR reported 27% EPS growth in its most recent report, while sales growth came in at 12%.
The company holds the No. 2 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
